Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Cardiovascular Benefits of SGLT2 Inhibitors: A Class Effect?

Mar 21 2017

• By John Davis

glucometer for glucose level and healthy organic food on a white background. Diabetes concept

Related Content

Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too

Dec 05 2016

Diabetes Treatment Shift Coming? Cleveland Clinic’s Nissen Declares Victory

Oct 31 2016

EASD 2016: Semaglutide Steals The Show With Impressive Cardiovascular Outcomes Data

Sep 16 2016

BI/Lilly's Jardiance Is First Diabetes Drug With CV Benefit Claim

Dec 02 2016

Related Companies

Boehringer Ingelheim GmbH

Eli Lilly and Company

AstraZeneca PLC

Novo Nordisk A/S

Additional Topics

Clinical Trials Research & Development Metabolic Disorders BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window